Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Phase 2 Pilot Study of VLX-1005 Versus Placebo in Participants With Suspected Heparin Induced Thrombocytopenia Treated With Background Standard of Care

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Phase 2 Pilot Study of VLX-1005 Versus Placebo in Participants With Suspected Heparin Induced Thrombocytopenia Treated With Background Standard of Care

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VLX-1005 (Primary)
  • Indications Heparin-induced thrombocytopenia and thrombosis syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ALATHEA
  • Sponsors Veralox Therapeutics

    • Most Recent Events

    • 09 Jan 2025 According to a Veralox Therapeutics media release, this trial is enrolling at 14 clinical sites.
    • 27 Sep 2023 Status changed from not yet recruiting to recruiting.
    • 20 Jun 2023 According to a Veralox Therapeutics media release, the company received $24 million in funding for this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top